Regulation of GLUT transporters by flavonoids in androgen-sensitive and-insensitive prostate cancer cells

Endocrinology (United States)

Volumn 155, Issue 9, 2014, Pages 3238-3250

  Gonzalez Menendez, Pedro ^a   Hevia, David ^a   Rodriguez Garcia, Aida ^a   Mayo, Juan C ^a   Sainz, Rosa M ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; APIGENIN; DAIDZEIN; DEOXYGLUCOSE; FLAVONOID; GENISTEIN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; INSULIN; PHLORETIN; SLC2A1 PROTEIN, HUMAN; SLC2A4 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CLONE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG STRUCTURE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IC50; IMMUNOCYTOCHEMISTRY; INSULIN SENSITIVITY; MOLECULAR DOCKING; PHENOTYPE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BINDING SITE; CHEMISTRY; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; BINDING SITES; CELL LINE, TUMOR; FLAVONOIDS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 4; HUMANS; MALE; MOLECULAR DOCKING SIMULATION; PROSTATIC NEOPLASMS;

EID: 84907043865     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1260     Document Type: Article

References (54)

1. Warburg O. On the origin of cancer cells. Science. 1956;3191:309-314.
2. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Reviews Drug Discov. 2011;10(9):671-684.
3. Van der Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033.
4. De Berardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic gly-colysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49):19345-19350.
5. De Berardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11-20.
6. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230-233.
7. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325-337.
8. Szablewski L. Expression of glucose transporters in cancers. Biochim Biophys Acta. 2012;1835(2):164-169.
9. Burant CF, Bell GI. Mammalian facilitative glucose transporters: evidence for similar substrate recognition sites in functionally mo-nomeric proteins. Biochemistry. 1992;31(42):10414-10420.
10. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol. 2002;3(4):267-277.
11. Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22(9):963-969.
12. Vaz CV, Alves MG, Marques R, et al. Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. Int J Biochem Cell Biol. 2012;44(11):2077-2084.
13. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-ki-nase/proteinkinaseBinprostate cancer cells. Clin Cancer Res. 2003; 9(7):2416-2425.
14. Horii K, Suzuki Y, Kondo Y, et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res. 2007;5(4): 383-391.
15. Massie CE, Lynch A, Ramos-Montoya A, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. The EMBO journal. 2011;30(13):2719-2733.
16. Singh G, Lakkis CL, Laucirica R, Epner DE. Regulation of prostate cancer cell division by glucose. J Cell Physiol. 1999;180(3):431-438.
17. Bondy SJ, Iscoe NA, Rothwell DM, et al. Trends in hormonal management of prostate cancer: a population-based study in Ontario. Med Care. 2001;39(4):384-396.
18. Kim YS, Milner JA. Bioactive food components and cancer-specific metabonomic profiles. J Biomed Biotechnol. 2011;2011:721213.
19. Rastogi S, Banerjee S, Chellappan S, Simon GR. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett. 2007;257(2):244-251.
20. Pérez A, Ojeda P, Ojeda L, et al. Hexose transporter GLUT1 harbors several distinct regulatory binding sites for flavones and tyrphostins. Biochemistry. 2011;50(41):8834-8845.
21. Shenouda NS, Zhou C, Browning JD, et al. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer. 2004;49(2):200-208.
22. Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol. 2014;140:116-132.
23. Thelen P, Wuttke W, Seidlová-Wuttke D. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer. J Steroid Biochem Mol Biol. 2014; 139:290-293.
24. Gao S, Liu GZ, Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate. 2004;59(2):214-225.
25. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52(4):673-751.
26. Rodriguez-Garcia A, Mayo JC, Hevia D, Quiros-Gonzalez I, Navarro M, Sainz RM. Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis. J Pineal Res. 2013;54(1):33-45.
27. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ. Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA. 1989;86(1):327-331.
28. Rago R, Mitchen J, Wilding G. DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem. 1990;191(1):31-34.
29. Yamamoto N, Ueda M, Sato T, et al Measurement of glucose uptake in cultured cells. Curr Protoc Pharmacol. 2011;Chapter 12:Unit 12. 14. 1-22.
30. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680-685.
31. Sun L, Zeng X, Yan C, Sun X, Gong X, Rao Y, Yan N. Crystal structure of a bacterial homologue of glucose transporters GLUT1-4. Nature. 2012;490(7420):361-366.
32. Salas-Burgos A, Iserovich P, Zuniga F, Vera JC, Fischbarg J. Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophysical journal. 2004;87(5):2990-2999.
33. Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem. 2006;49(11):3315-3321.
34. Zhang W, Liu Y, Chen X, Bergmeier SC. Novel inhibitors of basal glucose transport as potential anticancer agents. Bioorg Med Chem Lett. 2010;20(7):2191-2194.
35. Bubols GB, Vianna Dda R, Medina-Remon A, et al. The antioxidant activity of coumarins and flavonoids. Mini Rev Med Chem. 2013; 13(3):318-334.
36. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654-662.
37. Armoni M, Quon MJ, Maor G, et al. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo andin vitro. J Clin Endocrinol Metab. 2002; 87(11):5312-5324.
38. Harmon AW, Patel YM. Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res Treat. 2004;85(2):103-110.
39. Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem. 2012;113(2):553-562.
40. Chandler JD, Williams ED, Slavin JL, Best JD, Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer. 2003;97(8):2035-2042.
41. Vera JC, Reyes AM, Cárcamo JG, et al. Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1. The J biological chemistry. 1996; 271(15):8719-8724.
42. Lefevre PG, Marshall JK. The atachment ofphloretin and analogues to human erythrocytes in connection with inhibition of sugar transport. The J biological chemistry. 1959;234:3022-3026.
43. Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008;37(4): 426-431.
44. Vera JC, Reyes AM, Velásquez FV, et al. Direct inhibition of the hexose transporter GLUT1 by tyrosine kinase inhibitors. Biochemistry. 2001;40(3):777-790.
45. Bazuine M, van den Broek PJ, Maassen JA. Genistein directly inhibits GLUT4-mediated glucose uptake in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2005;326(2):511-514.
46. Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin down-regulates the hypoxia response genes: HIF-1a, GLUT-1, and VEGF in human pancreatic cancer cells. J Surg Res. 2011;167(2):173-181.
47. Cho KW, Lee OH, Banz WJ, Moustaid-Moussa N, Shay NF, Kim YC. Daidzein and the daidzein metabolite, equol, enhance adipocyte differentiation and PPARgamma transcriptional activity. J Nutr Biochem. 2010;21(9):841-847.
48. Cheong SH, Furuhashi K, Ito K, et al. Daidzein promotes glucose uptake through glucose transporter 4 translocation to plasma membrane in L6 myocytes and improves glucose homeostasis in Type 2 diabetic model mice. J Nutr Biochem. 2014;25(2):136-143.
49. Mahmoud AM, Zhu T, Parray A, et al. Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PloS One. 2013;8(10):e78479.
50. Wen J, Zhao Y, Li J, et al. Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells. Prostate. 2013;73(10):1069-1081.
51. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem. 2007;102(4):899-911.
52. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139(10):4252-4263.
53. Khayat ZA, McCall AL, Klip A. Unique mechanism of GLUT3 glucose transporter regulation by prolonged energy demand: increased protein half-life. The Biochemical journal. 1998;333(Pt 3):713-718.
54. Liu Y, Cao Y, Zhang W, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012;11(8):1672-1682.